Page 33 - Read Online

Page 26 of 28 Cheng et al. Cancer Drug Resist. 2025;8:46

117. Norling LV, Sampaio AL, Cooper D, Perretti M. Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte
trafficking. FASEB J. 2008;22:682-90. DOI PubMed
118. Buckanovich RJ, Facciabene A, Kim S, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and
disables immune therapy. Nat Med. 2008;14:28-36. DOI PubMed
119. Tan J, Fan W, Liu T, et al. TREM2 macrophages suppress CD8 T-cell infiltration after transarterial chemoembolisation in
+
+
hepatocellular carcinoma. J Hepatol. 2023;79:126-40. DOI PubMed
120. Engin AB, Engin A. Indoleamine 2,3-dioxygenase activity-induced acceleration of tumor growth, and protein kinases-related novel
therapeutics regimens. In: Engin AB, Engin A, editors. Protein kinase-mediated decisions between life and death. Cham: Springer
International Publishing; 2021. pp. 339-56. DOI
121. Herbert A, Ng H, Jessup W, et al. Hypoxia regulates the production and activity of glucose transporter-1 and indoleamine
2,3-dioxygenase in monocyte-derived endothelial-like cells: possible relevance to infantile haemangioma pathogenesis. Br J Dermatol.
2011;164:308-15. DOI PubMed
122. Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes
vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52:1475-85. DOI PubMed PMC
123. Groth C, Hu X, Weber R, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
Br J Cancer. 2019;120:16-25. DOI PubMed PMC
124. Khan O, Giles JR, McDonald S, et al. TOX transcriptionally and epigenetically programs CD8 T cell exhaustion. Nature.
+
2019;571:211-8. DOI PubMed PMC
125. Kim CG, Jang M, Kim Y, et al. VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal
cancers. Sci Immunol. 2019;4:eaay0555. DOI PubMed
126. Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol.
2018;15:310-24. DOI PubMed
127. Goumans MJ, Liu Z, ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res. 2009;19:116-27. DOI PubMed
128. Tian M, Neil JR, Schiemann WP. Transforming growth factor-β and the hallmarks of cancer. Cell Signal. 2011;23:951-62. DOI PubMed
PMC
129. Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med. 2012;44:1-9. DOI PubMed PMC
130. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and
challenges. Nat Rev Clin Oncol. 2018;15:325-40. DOI PubMed PMC
131. Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat
Rev Immunol. 2018;18:195-203. DOI PubMed PMC
132. Jiang M, Qin B, Luo L, et al. A clinically acceptable strategy for sensitizing anti-PD-1 treatment by hypoxia relief. J Control Release.
2021;335:408-19. DOI PubMed
133. Chen A, Yang F, Kuang J, et al. A versatile nanoplatform for broad-spectrum immunotherapy by reversing the tumor microenvironment.
ACS Appl Mater Interfaces. 2021;13:45335-45. DOI PubMed
134. Zhen X, Li Y, Yuan W, et al. Biointerface-engineered hybrid nanovesicles for targeted reprogramming of tumor microenvironment. Adv
Mater. 2024;36:e2401495. DOI PubMed
135. Wu J, Wang X, Chen L, et al. Oxygen microcapsules improve immune checkpoint blockade by ameliorating hypoxia condition in
pancreatic ductal adenocarcinoma. Bioact Mater. 2023;20:259-70. DOI PubMed PMC
136. Feng X, Chen Z, Liu Z, Fu X, Song H, Zhang Q. Self-delivery photodynamic-hypoxia alleviating nanomedicine synergizes with
anti-PD-L1 for cancer immunotherapy. Int J Pharm. 2023;639:122970. DOI PubMed
137. Fang T, Cao X, Wang L, Chen M, Deng Y, Chen G. Bioresponsive and immunotherapeutic nanomaterials to remodel tumor
microenvironment for enhanced immune checkpoint blockade. Bioact Mater. 2024;32:530-42. DOI PubMed PMC
138. Zhu L, Li J, Guo Z, Kwok HF, Zhao Q. Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes
persistent T cell immune activation for cancer immunotherapy. J Nanobiotechnology. 2022;20:521. DOI PubMed PMC
139. Zhang X, Bai J, Sun S, et al. Chiral nanoassembly remodels tumor microenvironment through non-oxygen-dependent depletion lactate
for effective photodynamic immunotherapy. Biomaterials. 2025;319:123203. DOI PubMed
140. He M, Zhang M, Xu T, et al. Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor
microenvironment with hypoxia relief. J Control Release. 2024;368:233-50. DOI
141. Chang CC, Dinh TK, Lee YA, et al. Nanoparticle delivery of MnO 2 and antiangiogenic therapy to overcome hypoxia-driven tumor
escape and suppress hepatocellular carcinoma. ACS Appl Mater Interfaces. 2020;12:44407-19. DOI PubMed
142. Bao Y, Li G, Li S, et al. Multifunctional tumor-targeting carbon dots for tumor microenvironment activated ferroptosis and
immunotherapy in cancer treatment. ACS Appl Mater Interfaces. 2023;15:56834-45. DOI PubMed
26